http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 02 Sep 2025 07:32:11 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Mergers+and+Acquisitions/Medicus+Pharma+completes+%242.97+million+acquisition+of+Antev+Limited/25281212.html <p>Medicus Pharma Ltd. (NASDAQ: MDCX) has completed its acquisition of 98.6% of the issued and outstanding shares of Antev Limited for approximately $2.97 million in cash and 1,603,164 common shares of Medicus, according to a company statement.</p> <p>Antev, a UK-based clinical-stage drug development company, is developing Teverelix, a GnRH antagonist for acute urinary retention and prostate cancer treatment in patients with high cardiovascular risk. Former Antev shareholders are entitled to receive up to approximately $65 million in additional contingent consideration tied to potential future FDA Phase 2 and New Drug Application approvals.</p> <p>Patrick J. Mahaffy, former chairman of Antev and former CEO http://www.streetinsider.com/Mergers+and+Acquisitions/Medicus+Pharma+completes+%242.97+million+acquisition+of+Antev+Limited/25281212.html Tue, 02 Sep 2025 07:32:11 -0400 CLVS MDCX PHRM http://www.streetinsider.com/Mergers+and+Acquisitions/Medicus+Pharma+completes+%242.97+million+acquisition+of+Antev+Limited/25281212.html <p>Medicus Pharma Ltd. (NASDAQ: MDCX) has completed its acquisition of 98.6% of the issued and outstanding shares of Antev Limited for approximately $2.97 million in cash and 1,603,164 common shares of Medicus, according to a company statement.</p> <p>Antev, a UK-based clinical-stage drug development company, is developing Teverelix, a GnRH antagonist for acute urinary retention and prostate cancer treatment in patients with high cardiovascular risk. Former Antev shareholders are entitled to receive up to approximately $65 million in additional contingent consideration tied to potential future FDA Phase 2 and New Drug Application approvals.</p> <p>Patrick J. Mahaffy, former chairman of Antev and former CEO http://www.streetinsider.com/Mergers+and+Acquisitions/Medicus+Pharma+completes+%242.97+million+acquisition+of+Antev+Limited/25281212.html Tue, 02 Sep 2025 07:32:11 -0400 CLVS MDCX PHRM http://www.streetinsider.com/Mergers+and+Acquisitions/Medicus+Pharma+completes+%242.97+million+acquisition+of+Antev+Limited/25281212.html <p>Medicus Pharma Ltd. (NASDAQ: MDCX) has completed its acquisition of 98.6% of the issued and outstanding shares of Antev Limited for approximately $2.97 million in cash and 1,603,164 common shares of Medicus, according to a company statement.</p> <p>Antev, a UK-based clinical-stage drug development company, is developing Teverelix, a GnRH antagonist for acute urinary retention and prostate cancer treatment in patients with high cardiovascular risk. Former Antev shareholders are entitled to receive up to approximately $65 million in additional contingent consideration tied to potential future FDA Phase 2 and New Drug Application approvals.</p> <p>Patrick J. Mahaffy, former chairman of Antev and former CEO http://www.streetinsider.com/Mergers+and+Acquisitions/Medicus+Pharma+completes+%242.97+million+acquisition+of+Antev+Limited/25281212.html Tue, 02 Sep 2025 07:32:11 -0400 CLVS MDCX PHRM http://www.streetinsider.com/Press+Releases/Medicus+Pharma+Ltd.+Completes+Acquisition+of+Antev+Limited/25281207.html <p>Antev is developing Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer collecting representing ~US$6 billion in potential market opportunity</p><p style="text-align: center;"><i>Patrick J. Mahaffy, a veteran pharma executive and the former Chairman of Antev, appointed to Medicus Board of Directors </i></p><p>Philadelphia, Pennsylvania--(Newsfile Corp. - September 2, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("<b>Medicus</b>" or the "<b>Company</b>"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, and Antev Limited ("<b>Antev</b>"), a UK-based clinical-stage drug development company, http://www.streetinsider.com/Press+Releases/Medicus+Pharma+Ltd.+Completes+Acquisition+of+Antev+Limited/25281207.html Tue, 02 Sep 2025 07:30:00 -0400 CLVS MDCX PHRM http://www.streetinsider.com/Press+Releases/Medicus+Pharma+Ltd.+Completes+Acquisition+of+Antev+Limited/25281207.html <p>Antev is developing Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer collecting representing ~US$6 billion in potential market opportunity</p><p style="text-align: center;"><i>Patrick J. Mahaffy, a veteran pharma executive and the former Chairman of Antev, appointed to Medicus Board of Directors </i></p><p>Philadelphia, Pennsylvania--(Newsfile Corp. - September 2, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("<b>Medicus</b>" or the "<b>Company</b>"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, and Antev Limited ("<b>Antev</b>"), a UK-based clinical-stage drug development company, http://www.streetinsider.com/Press+Releases/Medicus+Pharma+Ltd.+Completes+Acquisition+of+Antev+Limited/25281207.html Tue, 02 Sep 2025 07:30:00 -0400 CLVS MDCX PHRM http://www.streetinsider.com/Press+Releases/Medicus+Pharma+Ltd.+Completes+Acquisition+of+Antev+Limited/25281207.html <p>Antev is developing Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer collecting representing ~US$6 billion in potential market opportunity</p><p style="text-align: center;"><i>Patrick J. Mahaffy, a veteran pharma executive and the former Chairman of Antev, appointed to Medicus Board of Directors </i></p><p>Philadelphia, Pennsylvania--(Newsfile Corp. - September 2, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("<b>Medicus</b>" or the "<b>Company</b>"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, and Antev Limited ("<b>Antev</b>"), a UK-based clinical-stage drug development company, http://www.streetinsider.com/Press+Releases/Medicus+Pharma+Ltd.+Completes+Acquisition+of+Antev+Limited/25281207.html Tue, 02 Sep 2025 07:30:00 -0400 CLVS MDCX PHRM http://www.streetinsider.com/Newsfile/Medicus+Pharma+Ltd.+Completes+Acquisition+of+Antev+Limited/25281207.html <p>Antev is developing Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer collecting representing ~US$6 billion in potential market opportunity</p><p style="text-align: center;"><i>Patrick J. Mahaffy, a veteran pharma executive and the former Chairman of Antev, appointed to Medicus Board of Directors </i></p><p>Philadelphia, Pennsylvania--(Newsfile Corp. - September 2, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("<b>Medicus</b>" or the "<b>Company</b>"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, and Antev Limited ("<b>Antev</b>"), a UK-based clinical-stage drug development company, http://www.streetinsider.com/Newsfile/Medicus+Pharma+Ltd.+Completes+Acquisition+of+Antev+Limited/25281207.html Tue, 02 Sep 2025 07:30:00 -0400 CLVS MDCX PHRM http://www.streetinsider.com/Newsfile/Medicus+Pharma+Ltd.+Completes+Acquisition+of+Antev+Limited/25281207.html <p>Antev is developing Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer collecting representing ~US$6 billion in potential market opportunity</p><p style="text-align: center;"><i>Patrick J. Mahaffy, a veteran pharma executive and the former Chairman of Antev, appointed to Medicus Board of Directors </i></p><p>Philadelphia, Pennsylvania--(Newsfile Corp. - September 2, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("<b>Medicus</b>" or the "<b>Company</b>"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, and Antev Limited ("<b>Antev</b>"), a UK-based clinical-stage drug development company, http://www.streetinsider.com/Newsfile/Medicus+Pharma+Ltd.+Completes+Acquisition+of+Antev+Limited/25281207.html Tue, 02 Sep 2025 07:30:00 -0400 CLVS MDCX PHRM http://www.streetinsider.com/Newsfile/Medicus+Pharma+Ltd.+Completes+Acquisition+of+Antev+Limited/25281207.html <p>Antev is developing Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer collecting representing ~US$6 billion in potential market opportunity</p><p style="text-align: center;"><i>Patrick J. Mahaffy, a veteran pharma executive and the former Chairman of Antev, appointed to Medicus Board of Directors </i></p><p>Philadelphia, Pennsylvania--(Newsfile Corp. - September 2, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("<b>Medicus</b>" or the "<b>Company</b>"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, and Antev Limited ("<b>Antev</b>"), a UK-based clinical-stage drug development company, http://www.streetinsider.com/Newsfile/Medicus+Pharma+Ltd.+Completes+Acquisition+of+Antev+Limited/25281207.html Tue, 02 Sep 2025 07:30:00 -0400 CLVS MDCX PHRM http://www.streetinsider.com/SEC+Filings/Form++25-NSE+++++Clovis+Oncology%2C+Inc.++++++++++++++++++Filed+by%3A+Nasdaq+Stock+Market+LLC/21014440.html si-local-file:///var/storage/secattach/20221229/21014440.html http://www.streetinsider.com/SEC+Filings/Form++25-NSE+++++Clovis+Oncology%2C+Inc.++++++++++++++++++Filed+by%3A+Nasdaq+Stock+Market+LLC/21014440.html Thu, 29 Dec 2022 09:36:00 -0400 CLVS http://www.streetinsider.com/Corporate+News/NASDAQ+Announces+Delisting+of+Securities+of+Tuscan+Holdings+Corp.+II%3B+Clovis+Oncology%2C+Inc.%3B+ZyVersa+Therapeutics%2C+Inc.%3B+Otonomy%2C+Inc.%2C+and+Forward+Pharma+AS/21012326.html si-local-file:///var/storage/newsbody/2022/1228/21012326.html http://www.streetinsider.com/Corporate+News/NASDAQ+Announces+Delisting+of+Securities+of+Tuscan+Holdings+Corp.+II%3B+Clovis+Oncology%2C+Inc.%3B+ZyVersa+Therapeutics%2C+Inc.%3B+Otonomy%2C+Inc.%2C+and+Forward+Pharma+AS/21012326.html Wed, 28 Dec 2022 16:11:41 -0400 0IRP CLVS FWP OTIC THCA ZVSA http://www.streetinsider.com/Corporate+News/NASDAQ+Announces+Delisting+of+Securities+of+Tuscan+Holdings+Corp.+II%3B+Clovis+Oncology%2C+Inc.%3B+ZyVersa+Therapeutics%2C+Inc.%3B+Otonomy%2C+Inc.%2C+and+Forward+Pharma+AS/21012326.html si-local-file:///var/storage/newsbody/2022/1228/21012326.html http://www.streetinsider.com/Corporate+News/NASDAQ+Announces+Delisting+of+Securities+of+Tuscan+Holdings+Corp.+II%3B+Clovis+Oncology%2C+Inc.%3B+ZyVersa+Therapeutics%2C+Inc.%3B+Otonomy%2C+Inc.%2C+and+Forward+Pharma+AS/21012326.html Wed, 28 Dec 2022 16:11:41 -0400 0IRP CLVS FWP OTIC THCA ZVSA http://www.streetinsider.com/Corporate+News/NASDAQ+Announces+Delisting+of+Securities+of+Tuscan+Holdings+Corp.+II%3B+Clovis+Oncology%2C+Inc.%3B+ZyVersa+Therapeutics%2C+Inc.%3B+Otonomy%2C+Inc.%2C+and+Forward+Pharma+AS/21012326.html si-local-file:///var/storage/newsbody/2022/1228/21012326.html http://www.streetinsider.com/Corporate+News/NASDAQ+Announces+Delisting+of+Securities+of+Tuscan+Holdings+Corp.+II%3B+Clovis+Oncology%2C+Inc.%3B+ZyVersa+Therapeutics%2C+Inc.%3B+Otonomy%2C+Inc.%2C+and+Forward+Pharma+AS/21012326.html Wed, 28 Dec 2022 16:11:41 -0400 0IRP CLVS FWP OTIC THCA ZVSA http://www.streetinsider.com/Corporate+News/NASDAQ+Announces+Delisting+of+Securities+of+Tuscan+Holdings+Corp.+II%3B+Clovis+Oncology%2C+Inc.%3B+ZyVersa+Therapeutics%2C+Inc.%3B+Otonomy%2C+Inc.%2C+and+Forward+Pharma+AS/21012326.html si-local-file:///var/storage/newsbody/2022/1228/21012326.html http://www.streetinsider.com/Corporate+News/NASDAQ+Announces+Delisting+of+Securities+of+Tuscan+Holdings+Corp.+II%3B+Clovis+Oncology%2C+Inc.%3B+ZyVersa+Therapeutics%2C+Inc.%3B+Otonomy%2C+Inc.%2C+and+Forward+Pharma+AS/21012326.html Wed, 28 Dec 2022 16:11:41 -0400 0IRP CLVS FWP OTIC THCA ZVSA http://www.streetinsider.com/Corporate+News/NASDAQ+Announces+Delisting+of+Securities+of+Tuscan+Holdings+Corp.+II%3B+Clovis+Oncology%2C+Inc.%3B+ZyVersa+Therapeutics%2C+Inc.%3B+Otonomy%2C+Inc.%2C+and+Forward+Pharma+AS/21012326.html si-local-file:///var/storage/newsbody/2022/1228/21012326.html http://www.streetinsider.com/Corporate+News/NASDAQ+Announces+Delisting+of+Securities+of+Tuscan+Holdings+Corp.+II%3B+Clovis+Oncology%2C+Inc.%3B+ZyVersa+Therapeutics%2C+Inc.%3B+Otonomy%2C+Inc.%2C+and+Forward+Pharma+AS/21012326.html Wed, 28 Dec 2022 16:11:41 -0400 0IRP CLVS FWP OTIC THCA ZVSA http://www.streetinsider.com/Corporate+News/NASDAQ+Announces+Delisting+of+Securities+of+Tuscan+Holdings+Corp.+II%3B+Clovis+Oncology%2C+Inc.%3B+ZyVersa+Therapeutics%2C+Inc.%3B+Otonomy%2C+Inc.%2C+and+Forward+Pharma+AS/21012326.html si-local-file:///var/storage/newsbody/2022/1228/21012326.html http://www.streetinsider.com/Corporate+News/NASDAQ+Announces+Delisting+of+Securities+of+Tuscan+Holdings+Corp.+II%3B+Clovis+Oncology%2C+Inc.%3B+ZyVersa+Therapeutics%2C+Inc.%3B+Otonomy%2C+Inc.%2C+and+Forward+Pharma+AS/21012326.html Wed, 28 Dec 2022 16:11:41 -0400 0IRP CLVS FWP OTIC THCA ZVSA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Clovis+Oncology%2C+Inc.+++++For%3A+Dec+16/20986783.html si-local-file:///var/storage/secattach/20221219/20986783.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Clovis+Oncology%2C+Inc.+++++For%3A+Dec+16/20986783.html Mon, 19 Dec 2022 17:03:00 -0400 CLVS http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Clovis+Oncology%2C+Inc.+++++For%3A+Dec+12/20961144.html si-local-file:///var/storage/secattach/20221213/20961144.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Clovis+Oncology%2C+Inc.+++++For%3A+Dec+12/20961144.html Tue, 13 Dec 2022 06:10:00 -0400 CLVS http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Clovis+Oncology%2C+Inc.+++++For%3A+Dec+11/20961134.html si-local-file:///var/storage/secattach/20221213/20961134.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Clovis+Oncology%2C+Inc.+++++For%3A+Dec+11/20961134.html Tue, 13 Dec 2022 06:07:00 -0400 CLVS http://www.streetinsider.com/Corporate+News/Clovis+Oncology+%28CLVS%29+Files+for+Chapter+11+Protection+and+Enters+into+Agreement+to+Sell+FAP-2286/20956289.html si-local-file:///var/storage/newsbody/2022/1212/20956289.html http://www.streetinsider.com/Corporate+News/Clovis+Oncology+%28CLVS%29+Files+for+Chapter+11+Protection+and+Enters+into+Agreement+to+Sell+FAP-2286/20956289.html Mon, 12 Dec 2022 07:22:26 -0400 CLVS http://www.streetinsider.com/Mergers+and+Acquisitions/Clovis+Oncology+%28CLVS%29+Files+for+Chapter+11+Protection+and+Enters+into+Agreement+to+Sell+FAP-2286/20956289.html si-local-file:///var/storage/newsbody/2022/1212/20956289.html http://www.streetinsider.com/Mergers+and+Acquisitions/Clovis+Oncology+%28CLVS%29+Files+for+Chapter+11+Protection+and+Enters+into+Agreement+to+Sell+FAP-2286/20956289.html Mon, 12 Dec 2022 07:22:26 -0400 CLVS http://www.streetinsider.com/Press+Releases/Clovis+Oncology+Files+for+Chapter+11+Protection+and+Enters+into+Agreement+to+Sell+FAP-2286/20955268.html si-local-file:///var/storage/newsbody/2022/1212/20955268.html http://www.streetinsider.com/Press+Releases/Clovis+Oncology+Files+for+Chapter+11+Protection+and+Enters+into+Agreement+to+Sell+FAP-2286/20955268.html Mon, 12 Dec 2022 00:18:00 -0400 A.05498056 A.19697252 CLVS O.00070507 O.03542932 O.07418235 http://www.streetinsider.com/Press+Releases/Clovis+Oncology+Files+for+Chapter+11+Protection+and+Enters+into+Agreement+to+Sell+FAP-2286/20955268.html si-local-file:///var/storage/newsbody/2022/1212/20955268.html http://www.streetinsider.com/Press+Releases/Clovis+Oncology+Files+for+Chapter+11+Protection+and+Enters+into+Agreement+to+Sell+FAP-2286/20955268.html Mon, 12 Dec 2022 00:18:00 -0400 A.05498056 A.19697252 CLVS O.00070507 O.03542932 O.07418235 http://www.streetinsider.com/Press+Releases/Clovis+Oncology+Files+for+Chapter+11+Protection+and+Enters+into+Agreement+to+Sell+FAP-2286/20955268.html si-local-file:///var/storage/newsbody/2022/1212/20955268.html http://www.streetinsider.com/Press+Releases/Clovis+Oncology+Files+for+Chapter+11+Protection+and+Enters+into+Agreement+to+Sell+FAP-2286/20955268.html Mon, 12 Dec 2022 00:18:00 -0400 A.05498056 A.19697252 CLVS O.00070507 O.03542932 O.07418235 http://www.streetinsider.com/Press+Releases/Clovis+Oncology+Files+for+Chapter+11+Protection+and+Enters+into+Agreement+to+Sell+FAP-2286/20955268.html si-local-file:///var/storage/newsbody/2022/1212/20955268.html http://www.streetinsider.com/Press+Releases/Clovis+Oncology+Files+for+Chapter+11+Protection+and+Enters+into+Agreement+to+Sell+FAP-2286/20955268.html Mon, 12 Dec 2022 00:18:00 -0400 A.05498056 A.19697252 CLVS O.00070507 O.03542932 O.07418235